Fea Antonio

A Prospective Randomized Trial Comparing Hydrus and iStent Microinvasive Glaucoma Surgery Implants for Standalone Treatment of Open-Angle Glaucoma: The COMPARE Study.

Standalone MIGS in OAG with the Hydrus resulted in a higher surgical success rate and fewer medications compared with the 2-iStent procedure. The 2 MIGS devices have similar safety profiles.

Three-Year Results of Hydrus Microstent with Phacoemulsification.

Effectiveness and Safety of XEN45 in Eyes With High Myopia and Open Angle Glaucoma.

Although the Xen implant effectively lowered IOP in highly myopic eyes with glaucoma, the incidence of hypotony was high, and in most cases, resolved within the first month with medical management and monitoring.

Italian glaucoma virtual clinics: Developing a consensus for remote patient management.

This Delphi panel provides guidance for implementing glaucoma virtual clinics in Italy, establishing guidelines on patient selection, required assessments and staffing needs.

Ocular drug delivery systems: glaucoma patient perceptions from a German university hospital eye clinic.

ODD for the treatment of glaucoma were broadly deemed acceptable by patients in this study.

Effectiveness and safety of XEN45 implant over 12 months of follow-up: data from the XEN-Glaucoma Treatment Registry.

Over 1-year follow-up, XEN45 alone or in combination with phacoemulsification, had comparable success rates and effectively and safely lowered IOP and the need for OHM.

A Randomized Trial of a Schlemm's Canal Microstent with Phacoemulsification for Reducing Intraocular Pressure in Open-Angle Glaucoma.

Intraocular pressure was clinically and statistically significantly lower at 2 years in the Hydrus plus CS group compared with the CS alone group, with no differences in safety.